AP3D1 and colorectal carcinoma: OPTN, which is lost in early-stage human colorectal cancer, interacts with AP3D1 to hinder its recognition of IFNGR1, thereby maintaining IFNGR1 stability and the integrity of downstream MHC-I signaling, which promotes antigen presentation to T cells and inhibits CRC progression (Fig. 3c).300 This work suggests that targeting IFNGR1 palmitoylation might be a new strategy for promoting immune checkpoint therapy in CRC.